101 related articles for article (PubMed ID: 10841158)
1. Treatment of lympho-proliferative disease with rituximab.
Niedermeyer J; Hoffmeyer F; Hertenstein B; Hoeper MM; Fabel H
Lancet; 2000 Feb; 355(9202):499. PubMed ID: 10841158
[No Abstract] [Full Text] [Related]
2. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression.
Mozzanica N; Cattaneo A; Fracchiolla N; Boneschi V; Berti E; Gronda E; Mangiavacchi M; Finzi AF; Neri A
J Heart Lung Transplant; 1997 Sep; 16(9):964-8. PubMed ID: 9322148
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
Jericho H; Weinstein J; Melin-Aldana H; Leuer KC; Wyers M; Alonso EM; Ekong UD
J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):e2-4. PubMed ID: 24378523
[No Abstract] [Full Text] [Related]
4. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
Balamuth NJ; Nichols KE; Paessler M; Teachey DT
J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy.
Castagnola E; Dallorso S; Faraci M; Morreale G; Di Martino D; Cristina E; Scarso L; Lanino E
J Hematother Stem Cell Res; 2003 Feb; 12(1):9-10. PubMed ID: 12662431
[No Abstract] [Full Text] [Related]
6. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma.
Sirvent-Von Bueltzingsloewen A; Sirvent N; Morand P; Cassuto JP
Med Pediatr Oncol; 2003 Jun; 40(6):408-9. PubMed ID: 12692818
[No Abstract] [Full Text] [Related]
7. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
Cook RC; Connors JM; Gascoyne RD; Fradet G; Levy RD
Lancet; 1999 Nov; 354(9191):1698-9. PubMed ID: 10568575
[TBL] [Abstract][Full Text] [Related]
8. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.
Daibata M; Bandobashi K; Kuroda M; Imai S; Miyoshi I; Taguchi H
J Virol; 2005 May; 79(9):5875-9. PubMed ID: 15827204
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of EBV-positive low grade B-cell lymphoma.
Diamantopoulos PT; Polonyfi K; Sofotasiou M; Papadopoulou V; Kalala F; Iliakis T; Zervakis K; Tsilimidos G; Kouzis P; Kyrtsonis MC; Vassilakopoulos T; Angelopoulou M; Siakantaris M; Vayopoulos G; Kollia P; Pangalis G; Viniou NA
Anticancer Res; 2013 Dec; 33(12):5693-8. PubMed ID: 24324119
[TBL] [Abstract][Full Text] [Related]
10. Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection.
Ramos-Casals M; López-Guillermo A; Brito-Zerón P; Cervera R; Font J;
Lupus; 2004; 13(12):969-71. PubMed ID: 15645755
[No Abstract] [Full Text] [Related]
11. Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
Shinohara A; Asai T; Izutsu K; Ota Y; Takeuchi K; Hangaishi A; Kanda Y; Chiba S; Motokura T; Kurokawa M
Leuk Lymphoma; 2007 Feb; 48(2):418-20. PubMed ID: 17325908
[No Abstract] [Full Text] [Related]
12. Epstein-Barr viral infection and posttransplantation lymphoproliferative disorders.
Rustgi VK
Liver Transpl Surg; 1995 Sep; 1(5 Suppl 1):100-8. PubMed ID: 9346606
[No Abstract] [Full Text] [Related]
13. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
15. [Virus, immunosuppression, and the kidney transplant recipient].
Alberú J; Villasís A
Rev Invest Clin; 2005; 57(4):582-95. PubMed ID: 16315643
[No Abstract] [Full Text] [Related]
16. A study of Epstein-Barr virus infections in heart and heart and lung transplant recipients.
Wreghitt TG; Sargaison M; Sutehall G; Woodward CG; Scott J; English TA; Wallwork J
Transplant Proc; 1989 Feb; 21(1 Pt 3):2502-3. PubMed ID: 2539676
[No Abstract] [Full Text] [Related]
17. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
Dillman RO
J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
[No Abstract] [Full Text] [Related]
18. NICE announces guidelines for use of rituximab.
Mayor S
BMJ; 2003 Oct; 327(7418):766. PubMed ID: 14525854
[No Abstract] [Full Text] [Related]
19. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
[TBL] [Abstract][Full Text] [Related]
20. Regression of cutaneous intravascular lymphoma with rituximab.
Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
